HK Stock Market Move | SKB BIO-B (06990) rose more than 4% after the performance report, with annual revenue increasing by 6.46% year-on-year. Products such as Jia Tailai have started commercialization.

SKB BIO-B (06990) rose by more than 4% after the performance announcement, and as of the time of this report, it rose by 3.37% to 411 Hong Kong dollars, with a turnover of 1.04 billion Hong Kong dollars. On the news front, on March 23, SKB BIO-B released its annual performance for the year ended December 31, 2025. The company achieved revenue of 2.058 billion yuan, an increase of 6.46% year-on-year; the net loss attributable to equity shareholders of the company was 382 million yuan; research and development expenses were 1.32 billion yuan, an increase of 9.41% year-on-year; and the loss per share was 1.66 yuan. The announcement stated that the increase in revenue was mainly attributed to a 543 million yuan increase in revenue from drug sales. The announcement also mentioned that the company has obtained market approval for sac-TMT (Jiatailai), Tagore monoclonal antibody (Ketailei), Situ Xi monoclonal antibody N01 (Datelai), and Boduqu curcumin monoclonal antibody (Shutailai), and has begun commercialization. The company has also submitted an NDA for fulmarinibrate (Ningtailai) capsules and expects to start commercialization in the first half of 2027 after regulatory communication and market approval. The company's three commercialized products, sac-TMT (Jiatailai), Tagore monoclonal antibody (Ketailei), and Situ Xi monoclonal antibody N01 (Datelai), have been successfully included in the National Medical Insurance Drug List for the first time, which officially took effect on January 1, 2026.